Cholesterol drug may block colon cancer in colitis patients
NCT ID NCT04767984
First seen Nov 01, 2025 · Last updated Apr 24, 2026 · Updated 25 times
Summary
This study tests whether atorvastatin, a widely used cholesterol medication, can reduce the risk of colon cancer in people with long-standing ulcerative colitis who carry a specific genetic mutation (P53). About 42 participants will receive either atorvastatin or a placebo, and researchers will measure changes in cancer-related markers from colonoscopy biopsies. The goal is to find a safe, affordable way to prevent cancer in this high-risk group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
-
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
Conditions
Explore the condition pages connected to this study.